Buy Rating for Sanofi: Strong Growth and Attractive Valuation Amidst Pipeline Optionality and Strategic Leadership

Leerink Partners analyst David Risinger has reiterated their bullish stance on SNYNF stock, giving a Buy rating on May 10.

David Risinger has given his Buy rating due to a combination of factors indicating Sanofi’s strong growth potential and attractive valuation. He emphasizes the company’s solid growth outlook extending into the early 2030s, underpinned by a stable portfolio without major loss of exclusivity (LOE) events expected for nearly seven years. Further boosting confidence is the significant optionality within Sanofi’s pipeline, including the imminent Phase 3 results for tolebrutinib in nonrelapsing secondary progressive multiple sclerosis, which could be a key near-term catalyst. The company’s valuation is also compelling, trading at an attractive multiple relative to projected 2025 earnings per share.
Additionally, the leadership team’s recent strategic hires, such as CFO Francois-Xavier Roger and R&D Head Houman Ashrafian, are poised to accelerate performance with their extensive pharmaceutical experience and fresh perspectives. Sanofi’s differentiated growth prospects are also notable, with Dupixent’s low market penetration offering substantial room for expansion across multiple indications. Furthermore, recent blockbuster launches and a robust pipeline, including a suite of immunology and inflammation candidates, position the company well for sustained innovation and market leadership.

According to TipRanks, Risinger is a 5-star analyst with an average return of 11.5% and a 58.87% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Eli Lilly & Co, and AbbVie.

In another report released on May 10, UBS also maintained a Buy rating on the stock with a €110.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Sanofi (SNYNF) Company Description:

Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities. This segment also includes all associates whose activities are related to pharmaceuticals. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for its Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The company was founded in 1973 and is headquartered in Paris, France.